Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

September 14, 2019

Study Completion Date

September 14, 2019

Conditions

Hyperphosphatemia

Interventions

DRUG

Ferric Citrate

One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.

Trial Locations (1)

Kaiser Permanente Los Angeles Medical Center, Los Angeles